FDA authorizes Aletta robotic blood draw device

The U.S. Food and Drug Administration (FDA) has authorized Aletta, a robotic device developed by the Dutch company Vitestro, to perform autonomous blood draws in outpatient settings. The system uses a combination of near-infrared light, ultrasound, and Doppler technology to map vascular networks and identify suitable veins, distinguishing them from arteries to ensure safety.

Aletta is designed to manage the entire venipuncture process, including applying a tourniquet, disinfecting the skin, inserting the needle, managing collection tubes, and applying a bandage. While highly automated, the device requires human supervision; a trained professional must initiate the procedure and can oversee up to three machines simultaneously.

The introduction of this technology comes amid a growing shortage of trained phlebotomists in the United States. While the FDA views the automation as a potential solution to staffing shortages, labor organizations like UGL Salute have cautioned that robotics should serve as a support tool rather than a replacement for healthcare professionals. They emphasize that automation should be used to alleviate repetitive tasks and allow staff to focus more on direct patient care and reducing waiting lists.